0
Clinical Investigations: ASTHMA |

The Effect of Heliox in Acute Severe Asthma*: A Randomized Controlled Trial

Jonathan E. Kass, MD, FCCP; Carol A. Terregino, MD
Author and Funding Information

*From the Division of Pulmonary and Critical Care Medicine (Dr. Kass), and the Department of Emergency Medicine (Dr. Terregino), Cooper Hospital/University Medical Center, UMDNJ/Robert Wood Johnson School of Medicine, Camden, NJ.

Correspondence to: Jonathan E. Kass, MD, FCCP, Division of Pulmonary and Critical Care Medicine, 3 Cooper Plaza, Suite 312, Camden NJ 08103



Chest. 1999;116(2):296-300. doi:10.1378/chest.116.2.296
Text Size: A A A
Published online

Study objectives: To evaluate the effect of heliox on airflow obstruction and dyspnea in patients with acute severe asthma.

Design: A prospective, randomized, controlled study.

Setting: A university hospital.

Patients: Twenty-three patients presenting to the emergency department with acute severe asthma were randomized to receive 70%/30% heliox or 30% oxygen.

Measurements: Peak expiratory flow (PEF), dyspnea score, heart rate, respiratory rate (RR), and BP were measured at baseline and 20, 120, 240, 360, and 480 min after starting the test gas. After baseline, the PEF was measured by using the gas that was randomized to the treatment program.

Results: In the first 20 min, there was a 58.4% increase in percent predicted PEF (%PEF) in the heliox group (p < 0.001), whereas there was only a 10.1% increase in %PEF for the oxygen group (p > 0.1). Eighty-two percent of the heliox group had > 25% improvement in %PEF at 20 min, whereas only 17% of the oxygen group did (p < 0.01). The next significant improvement in %PEF in the heliox group occurred at 480 min. At the end of the study in the heliox group, the PEF did not significantly (p > 0.1) change immediately after the heliox was discontinued (270.6 to 264.2 L/min). In the heliox group in the first 20 min, there was a significant decrease in dyspnea score and RR (p < 0.05), but there were no further significant improvements for the rest of the study. In the oxygen group, no variables significantly improved until 360 min.

Conclusion: Heliox rapidly improves airflow obstruction and dyspnea in patients with acute severe asthma and may be useful as a therapeutic bridge until the corticosteroid effect occurs.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543